Last deal
Amount
Stage
Date
all rounds
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Strongbridge Biopharma
Strongbridge Biopharma is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
Sector
Subsector
Location
total rounds
total raised
Kadmon
Kadmon Corporation is a biopharmaceutical company specializing in treatments for hepatitis C.
Sector
Subsector
Location
total rounds
total raised
Curtana Pharmaceuticals
Curtana is a biopharmaceutical company that develops therapies for aggressive brain cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Dyax
Dyax Corp. is a biopharmaceutical company that develops and commercializes biotherapeutics for unmet medical needs.
Sector
Subsector
Keywords
Location
M&A Details1
Financials
Funding Rounds1
Number of Funding Rounds
Their latest funding was raised on 01.03.2008. Their latest investor Plough Penny Partners. Their latest round Post-IPO Equity
Plough Penny Partners
Plough Penny Partners is a private investment firm that invests in publicly traded and privately-held companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
Plough Penny Partners
Plough Penny Partners is a private investment firm that invests in publicly traded and privately-held companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders2
David Hung
Dr. David T. Hung, M.D. has been President, Chief Executive Officer, Director of Medivation, Inc. He is a member of the Board, since December 2004. Previously, Dr. Hung served as the President and Chief Executive Officer, and member of the board of directors, of Medivation Neurology, Inc. from its inception in September 2003 through December 2004, when it became the wholly owned subsidiary by merger. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999) and as President and Chief Executive Officer (1999-2001). Dr. Hung served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Hung is a director and member of the compensation committee of Opexa. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine, and an A.B. in Biology from Harvard College. Dr. Hung is a co-founder of Medivation, has served as the President and Chief Executive Officer since inception, and is responsible for the overall corporate strategy and selection of the product development candidates.
current job
organization founded
David Hung
Michael J. Cataldo
Mike is CEO of Convergent Dental, an early stage dental device company backed by Long River Ventures. The company has developed Solea, a device that will eliminate the drill for the majority of dental procedures and along with it, the noise, vibration and needle that cause patients to dread going to the dentist. This disruptive innovation was completed within 18 months of the company’s inception and is now rated best-in-class for both hard and soft tissue cutting by leading laser dentists. Prior to Convergent Dental, Mike was CEO of Cambridge Semantics, a Boston-based start-up which delivered the first development platform for the World Wide Web Consortium’s semantic technology standards. In 1997 he founded MediVation, which developed the first Electronic Provider Patient Interface connecting patients with their own doctors via the Internet. MediVation was acquired by McKesson in 2000.
current job
Michael J. Cataldo
Employee Profiles165
Facmt Javier Waksman
Head of drug safety and pharmacovigilance
Cantillon Eilers
Sales representative urology and oncology
Jill Liu
Senior director, technical accounting and external reporting